sales@intentmarketresearch.com
+1 463-583-2713
As per Intent Market Research, the Mice Model Market was valued at USD 1.4 billion in 2023 and will surpass USD 2.6 billion by 2030; growing at a CAGR of 8.8% during 2024 - 2030.
CRISPR / Cas9 Technology Segment to Hold the Largest Market Share
In 2023, the CRISPR / Cas9 technology held the largest market share. This dominance is primarily due to CRISPR/Cas9's ability to provide precise and detailed insights into genetic variations, making it a valuable tool in the advancement of personalized medicine. By allowing researchers to manipulate specific genes with high accuracy, CRISPR/Cas9 facilitates the development of tailored drug therapies based on an individual’s unique genetic makeup. The widespread adoption of CRISPR/Cas9 is also driven by its efficiency in gene editing, lower cost, and faster results compared to older technologies. These advantages have accelerated its use in drug discovery, cancer research, and the study of complex diseases, enhancing its market position. As personalized medicine and genetic research continue to advance, the CRISPR/Cas9 segment is expected to maintain its leading role in the mice model market.
North America is Projected to Have the Largest Market Size During the Forecast Period
North America held the largest market share, followed closely by Europe. North America's leadership in the market is largely attributed to its strong support for research and development in innovative therapeutic areas. The region's robust infrastructure for scientific research, coupled with significant funding from both public and private sectors, has enabled the rapid development of novel therapies. Countries like the United States and Canada have been at the forefront of preclinical research, with an increasing number of research projects focused on drug discovery and genetic studies. This rise in preclinical research activities, along with ongoing advancements in biotechnology, is driving the demand for mice models in the region.
The report focuses on estimating the current market potential in terms of the total addressable market for all the segments, sub-segments, and regions. In the process, all the high-growth and upcoming technologies were identified and analyzed to measure their impact on the current and future market. The report also identifies the key stakeholders, their business gaps, and their purchasing behavior. This information is essential for developing effective marketing strategies and creating products or services that meet the needs of the target market. The report also covers a detailed analysis of the competitive landscape which includes major players, their recent developments, growth strategies, product benchmarking, and manufacturing operations among others. Also, brief insights on start-up ecosystem and emerging companies is also included as part of this report.
The report will help you answer some of the most critical questions in the Mice Model Market. A few of them are as follows:
Report Features |
Description |
Market Size (2023) |
USD 1.4 billion |
Forecasted Value (2030) |
USD 2.6 billion |
CAGR (2024 – 2030) |
8.8% |
Base Year for Estimation |
2023 |
Historic Year |
2022 |
Forecast Period |
2024 – 2030 |
Report Coverage |
Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments |
Segments Covered |
Mice Model Market By Model Type & Service (Model Type, Service), By Therapeutic Area (Oncology, Metabolic Diseases, Immunology, Neurology, Cardiovascular Diseases), By Technology (CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer), By Application (Drug Discovery & Development, Research Application, Personalized Medicine), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, CROs & CDMOs) |
Regional Analysis |
North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) |
Customization Scope |
Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements |
1. Introduction |
1.1. Market Definition |
1.2. Scope of the Study |
1.3. Research Assumptions |
1.4. Study Limitations |
2. Research Methodology |
2.1. Research Approach |
2.1.1. Top-Down Method |
2.1.2. Bottom-Up Method |
2.1.3. Factor Impact Analysis |
2.2. Insights & Data Collection Process |
2.2.1. Secondary Research |
2.2.2. Primary Research |
2.3. Data Mining Process |
2.3.1. Data Analysis |
2.3.2. Data Validation and Revalidation |
2.3.3. Data Triangulation |
3.Executive Summary |
3.1. Major Markets & Segments |
3.2. Highest Growing Regions and Respective Countries |
3.3. Impact of Growth Drivers & Inhibitors |
3.4. Regulatory Overview by Country |
4. Mice Model Market, by Model Type & Service (Market Size & Forecast: USD Million, 2022 – 2030) |
4.1. Model Type |
4.1.1. Inbred Mice |
4.1.2. Genetically Engineered Mice |
4.1.3. Hybrid/Congenic Mice |
4.1.4. Outbred Mice |
4.2. Service |
4.2.1. Breeding |
4.2.2. Cryopreservation |
4.2.3. Rederivation |
4.2.4. Quarantine |
4.2.5. Others |
5. Mice Model Market, by Therapeutic Area (Market Size & Forecast: USD Million, 2022 – 2030) |
5.1. Oncology |
5.2. Metabolic Diseases |
5.3. Immunology |
5.4. Neurology |
5.5. Cardiovascular Diseases |
5.6. Others |
6. Mice Model Market, by Technology (Market Size & Forecast: USD Million, 2022 – 2030) |
6.1. CRISPR / CAS9 |
6.2. Microinjection |
6.3. Embryonic Stem Cell Injection |
6.4. Nuclear Transfer |
6.5. Others |
7. Mice Model Market, by Application (Market Size & Forecast: USD Million, 2022 – 2030) |
7.1. Drug Discovery & Development |
7.2. Research Application |
7.3. Personalized Medicine |
8. Mice Model Market, by End User (Market Size & Forecast: USD Million, 2022 – 2030) |
8.1. Pharmaceutical & Biotechnology Companies |
8.2. Academic & Research Institutes |
8.3. CROs & CDMOs |
9. Regional Analysis (Market Size & Forecast: USD Million, 2022 – 2030) |
9.1. Regional Overview |
9.2. North America |
9.2.1. Regional Trends & Growth Drivers |
9.2.2. Barriers & Challenges |
9.2.3. Opportunities |
9.2.4. Factor Impact Analysis |
9.2.5. Technology Trends |
9.2.6. North America Mice Model Market, by Model Type & Service |
9.2.7. North America Mice Model Market, by Therapeutic Area |
9.2.8. North America Mice Model Market, by Technology |
9.2.9. North America Mice Model Market, by Application |
9.2.10. North America Mice Model Market, by End-User |
9.2.11. By Country |
9.2.11.1. US |
9.2.11.1.1. US Mice Model Market, by Model Type & Service |
9.2.11.1.2. US Mice Model Market, by Therapeutic Area |
9.2.11.1.3. US Mice Model Market, by Technology |
9.2.11.1.4. US Mice Model Market, by Application |
9.2.11.1.5. US Mice Model Market, by End-User |
9.2.11.2. Canada |
9.2.11.3. Mexico |
*Similar segmentation will be provided for each region and country |
9.3. Europe |
9.4. Asia-Pacific |
9.5. Latin America |
9.6. Middle East & Africa |
10. Competitive Landscape |
10.1. Overview of the Key Players |
10.2. Competitive Ecosystem |
10.2.1. Level of Fragmentation |
10.2.2. Market Consolidation |
10.2.3. Product Innovation |
10.3. Company Share Analysis |
10.4. Company Benchmarking Matrix |
10.4.1. Strategic Overview |
10.4.2. Product Innovations |
10.5. Start-up Ecosystem |
10.6. Strategic Competitive Insights/ Customer Imperatives |
10.7. ESG Matrix/ Sustainability Matrix |
10.8. Manufacturing Network |
10.8.1. Locations |
10.8.2. Supply Chain and Logistics |
10.8.3. Product Flexibility/Customization |
10.8.4. Digital Transformation and Connectivity |
10.8.5. Environmental and Regulatory Compliance |
10.9. Technology Readiness Level Matrix |
10.10. Technology Maturity Curve |
10.11. Buying Criteria |
11. Company Profiles |
11.1. Biocytogen |
11.1.1. Company Overview |
11.1.2. Company Financials |
11.1.3. Product/Service Portfolio |
11.1.4. Recent Developments |
11.1.5. IMR Analysis |
*Similar information will be provided for other companies |
11.2. Charles River Laboratories |
11.3. Cyagen |
11.4. GemPharmatech |
11.5. Harbour BioMed |
11.6. Inotiv |
11.7. Ozgene Pty Ltd. |
11.8. Taconic Biosciences, Inc. |
11.9. THE JACKSON LABORATORY |
11.10. TransCure bioServices |
12. Appendix |
A comprehensive market research approach was employed to gather and analyze data on the Mice Model Market. In the process, the analysis was also done to analyze the parent market and relevant adjacencies to measure the impact of them on the Mice Model Market. The research methodology encompassed both secondary and primary research techniques, ensuring the accuracy and credibility of the findings.
Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.
Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the Mice Model ecosystem. The primary research objectives included:
A combination of top-down and bottom-up approaches was utilized to analyze the overall size of the Mice Model Market. These methods were also employed to assess the size of various subsegments within the market. The market size assessment methodology encompassed the following steps:
To ensure the accuracy and reliability of the market size, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size assessment.